Prothena Corp. (NASDAQ:PRTA) shares were up 3% during trading on Thursday . The company traded as high as $52.93 and last traded at $51.46, with a volume of 403,216 shares trading hands. The stock had previously closed at $49.98.

A number of research analysts recently commented on PRTA shares. Royal Bank Of Canada reissued a “buy” rating on shares of Prothena Corp. in a research note on Wednesday, June 22nd. Credit Suisse Group AG reissued a “buy” rating on shares of Prothena Corp. in a research note on Friday, June 10th. Zacks Investment Research raised Prothena Corp. from a “sell” rating to a “hold” rating in a research note on Friday, May 6th. Wedbush reissued an “outperform” rating and issued a $77.00 target price on shares of Prothena Corp. in a research note on Wednesday, August 3rd. Finally, Barclays PLC increased their target price on Prothena Corp. from $60.00 to $70.00 and gave the company an “overweight” rating in a research note on Thursday, August 4th. One research analyst has rated the stock with a hold rating and five have given a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and a consensus price target of $76.60.

The firm’s market cap is $1.80 billion. The stock’s 50 day moving average is $53.93 and its 200 day moving average is $44.44.

Prothena Corp. (NASDAQ:PRTA) last released its quarterly earnings data on Tuesday, August 2nd. The company reported ($1.18) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.91) by $0.27. The firm had revenue of $0.33 million for the quarter, compared to analysts’ expectations of $0.39 million. The company’s revenue for the quarter was up 22.2% on a year-over-year basis. On average, equities analysts anticipate that Prothena Corp. will post ($4.25) earnings per share for the current fiscal year.

In related news, insider Arthur W. Homan sold 9,375 shares of the firm’s stock in a transaction on Wednesday, July 20th. The shares were sold at an average price of $52.14, for a total transaction of $488,812.50. Following the sale, the insider now owns 9,375 shares in the company, valued at $488,812.50. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, insider Arthur W. Homan sold 3,125 shares of the firm’s stock in a transaction on Thursday, September 1st. The shares were sold at an average price of $52.16, for a total transaction of $163,000.00. Following the sale, the insider now owns 3,125 shares in the company, valued at approximately $163,000. The disclosure for this sale can be found here.

Prothena Corporation Public Limited Company is a global biotechnology company. The Company is focused on the discovery, development and commercialization of immunotherapies for the treatment of diseases that involve protein misfolding or cell adhesion. The Company’s clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson’s disease and other related synucleinopathies (PRX002), and inflammatory diseases, including psoriasis (PRX003).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.